August 18, 2010

EXITING ACOR WITH PROFIT RIGHT HERE AT $32.61.

Our negative thesis on Acordia Therapeutics (ACOR) has not changed. However we are positive on the group, therefore we will exit the entire position right here and plan to short again on spikes up. For readers’ convenience an earlier partial post is copied below:

Our thesis has not changed in that Ampyra is not a very good drug, although Wall Street has termed it a blockbuster drug.

In the short term, the bulls may be right. For the first time MS patients with difficulty in walking have hope. MS patients, in general tend to be very knowledgeable about new drugs and as such they are likely to demand that neurologists prescribe Ampyra.

… Please click here or the title below to read more.

August 18, 2010

SCALING IN THE TBT POSITION

Our long time readers are well aware that the ZYX Change Method Trade Management Guidelines call for scaling in the positions. Yesterday, we scaled in our first short in (TBT) UltraShort 20+ Year Treasury ProShares at $32.50. Today we scaled in the second tranche at $31.96. We will continue to scale in on spikes lower based on technicals.

… Please click here or the title below to read more.

August 18, 2010